Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: A pilot project
| Autor: | Jeffrey Chan, Nancy Ribeiro, Maria Green, Markus Tservistas, Felix Ratjen, Kitty Leung, Allan L. Coates, Manfred Keller, Martin Charron, Emily Louca |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Time Factors Cystic Fibrosis Pilot Projects Cystic fibrosis Pseudomonas infection Administration Inhalation medicine Tobramycin Humans Pseudomonas Infections Lung Inhalation business.industry Nebulizers and Vaporizers Respiratory disease Middle Aged medicine.disease Anti-Bacterial Agents Surgery Nebulizer Treatment Outcome medicine.anatomical_structure Inhaled tobramycin Anesthesia Pediatrics Perinatology and Child Health business medicine.drug |
| Zdroj: | Pediatric Pulmonology. 43:753-759 |
| ISSN: | 1099-0496 8755-6863 |
| Popis: | Background Patients with cystic fibrosis spend as much 30 min a day inhaling tobramycin. Could a new rapid system deposit the equivalent amount of tobramycin faster? Methods Six healthy adult males inhaled 5 ml (300 mg) of tobramycin from a breath enhanced nebulizer and either 125 mg (n = 3) or 150 mg (n = 3) from a vibrating membrane system with a large or small aerosol mixing chamber respectively. A radiolabel was added to the solution and shown to “track” with the tobramycin. Imaging was done with a dual headed gamma camera. Because the radiolabel will be cleared by mucociliary action during administration, algorithms were developed to allow the comparison of a slower system to a faster one. Results Both formulations were well tolerated. The lung deposition was 16.6 ± 3.2% (mean ± SD) of the charge dose delivered in 10.9 ± 1.0 min for the breath enhanced nebulizer versus 32.0 ± 5.1% delivered in 2.5 ± 0.4 min from the vibrating membrane system. The absolute pulmonary delivery of tobramycin was 49.9 ± 9.6 versus 43.9 ± 4.8 mg for the two systems respectively, differences that were statistically significant (pair t-test) but unlikely to be clinically significant. There was a similar deposition of tobramycin for the 125 and 150 mg dose. Conclusions It is possible to deliver an equivalent amount of tobramycin in a shorter period of time with the new vibrating membrane system and a more concentrated formulation. These data will allow the design of a comparison in patients with CF. Pediatr Pulmonol. 2008; 43:753–759. © 2008 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text